News
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project
Enschede, The Netherlands, and Hampton, UK - April 18, 2023 – 20Med Therapeutics, a leader in non-viral delivery and development of gene therapies and vaccines, and Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic m...
Read More20Med Therapeutics and CEPI Sign Agreement to Advance ThermoStable Vaccines Technology
· CEPI to initially provide up to USD850,000 to 20Med to advance development of 20Med’s bioresponsive polymeric nanoparticle platform for mRNA stabilization and delivery. · 20Med vaccine technology could improve access to mRNA vaccines by removin...
Read More20Med Therapeutics to Participate in the New Cancer Research Consortium Oncode-PACT
Leiden, 15 April 2022 - The National Growth Fund invests 325 million euro in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs. This has just been announced during the press conference by Jeroen Dijsselbloem, chairman of th...
Read More20Med Therapeutics started research into mRNA vaccines against variants of the SARS-CoV-2 Coronavirus
The SARS-CoV-2 pandemic has shown the need to be prepared for an outbreak of an infectious disease. It spurred one of the most promising scientific breakthroughs in the last century – the development and acceptance of a new class of vaccines based on mRNA. T...
Read More20Med Therapeutics has an open PhD position in the ITN CARTHAGO program aimed at developing non-viral gene therapy for the treatment of osteoarthritis.
Leiden, The Netherlands, October 1, 2020, 20Med Therapeutics today announced its involvement in the EC funded Horizon 2020 Marie Curie Innovative Training Network (ITN) CARTHAGO project. CARTHAGO offers 15 PhD positions with different partners across Europe. O...
Read More20Med Therapeutics expands its R&D team at the Leiden BioScience Park in The Netherlands
To support the development of its growing pipeline of mRNA based vaccines and therapeutics 20Med Therapeutics is expanding its R&D capacity by opening an additional laboratory in Leiden. Originally founded out of the University of Twente, 20Med’s research op...
Read More20Med Therapeutics appoints Allard Kaptein to Supervisory Board
RELEASED ON OCTOBER 28, 2019. ENSCHEDE, The Netherlands, Oc. 28, 2019 – 20Med Therapeutics BV, a biotechnology company developing innovative nanoparticles for delivery of RNA therapeutics today announced the appointment of Dutch biotech veteran and serial ent...
Read More20Med Therapeutics secures new financing for accelerated development of the 20Med Nanogel technology for the delivery of RNA therapeutics
RELEASED ON NOVEMBER 2, 2017. Please find the document here...
Read More